Osman HATİPOĞLU, Gündeniz ALTIAY, Erhan TABAKOĞLU, Levent ÖZDEMİR, Burcu ÖZDEMİR

Cisplatin-Dependent Nephrotoxicity in Patients with Lung Cancer

OBJECTIVEThe aim of the present study was to investigate nephrotoxicity development ratios and clinical resultsof nephrotoxicity in patients diagnosed with lung cancer who received cisplatin in chemotherapyprotocol.METHODSA total of 170 lung cancer patients were enrolled in the present prospective study. Renal functions wererecorded for each patient before and after chemotherapy. Nephrotoxicity was defined as doubling in plasmacreatinine concentration. Modification in treatment due to nephrotoxicity (reduction in cisplatin dosage,cisplatin interruption, or discontinuation of chemotherapy) was recorded during chemotherapy courses.RESULTSDecreasement of creatinine clearance levels was observed following each course of chemotherapy, butwas especially noteworthy following the 1st and 5th courses (p=0.002; p=0.007, respectively). Nephrotoxicitywas observed in 19 of the 170 patients (11%), in 10 of whom (53%) cisplatin dosage was reduced,and in 8 of whom (42%), cisplatin treatment was interrupted. Chemotherapy was discontinued in 1patient (5%).CONCLUSIONParticularly following the fourth course, chemotherapy must be carefully administered due to risk of nephrotoxicity.

PDF

___

1. Davis S, Kessler W, Haddad BM, Maesaka JK. Acute renal tubular dysfunction following cis-dichlorodiammine platinum therapy. J Med 1980;11(2-3):133-41.
2. Links M, Lewis C. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs 1999;57(3):293-308.
3. Taguchi T, Nazneen A, Abid MR, Razzaque MS. Cisplatin-associated nephrotoxicity and pathological events. Contrib Nephrol 2005;148:107-21.
4. Saleh S, El-Demerdash E. Protective effects of L-arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide. Basic Clin Pharmacol Toxicol 2005;97(2):91-7.
5. Eren E, Ata A, Arıcan A. Drugs used in the treatment of cancer and nephrotoxicity. Deu Med J 2012;26(3):229- 35.
6. Anand AJ, Bashey B. Newer insights into cisplatin nephrotoxicity. Ann Pharmacother 1993;27(12):1519- 25.
7. Kurt E, Evrensel T, Gönüllü G, Kanat Ö, Demiray M, Arslan M, et al. Cisplatin-Induced Renal Toxicity and Evaluation of the Efficacy of Synthetic Oral Prostaglandin E1 Analogue.Uludağ Üniversitesi Tıp Fakültesi Dergisi 2002;28(2):17-20.
8. Erkurt MA, Kuku İ, Kaya E, Aydoğdu İ. Cancer Chemotherapy and Kidney. İnönü Üniversitesi Tıp Fakültesi Dergisi 2009;16(1)63-8.